REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Carl Harald Janson leads Akinion Pharmaceuticals AB

(C) Karolinska Development AB09-01-2012. Akinion Pharmaceuticals AB, a Karolinska Development AB portfolio company, announced today the appointment of Carl Harald Janson as new CEO. Carl Harald Janson, MD, PhD and CEFA, has over 25 years of experience in medicine, pharmaceutical development and asset management

 

Carl Harald Janson served as Investment Manager at Karolinska Development from 2008 to 2011. He holds an MD and PhD from Karolinska Institutet and is a Certified European Financial Analyst (CEFA) from Stockholm School of Economics. Carl Harald has over 25 years of experience in medicine, pharmaceutical development and asset management including from Astra Arcus, Hagströmer & Qviberg Fondkommission, Danske Securities and Carnegie Investment Bank. He is currently Chairman of the Board of Dilaforette Holding and Board Director of Axelar, Oncopeptides, Clanotech and Akinion Pharmaceuticals.

Source: Akinion Pharmaceuticals

 

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

 

Related Articles

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

 

Doing our business a little bit differently than the others in industry

Dr. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk

 

Triggering Regenerative Functions with Transplanted Cells and Small Molecules

Prof. Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville


Stem Cell Insights Collection 2010

Issues and Evaluation from Pharma Leaders

 

Gillies O’Bryan-Tear to provide leadership for Algeta’s phase III trial

Dr Gillies O'Bryan-TearJuly 2009. The appointment ends a difficult period for Algeta.

 

 

 

 

 

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

enquiry, no PR, 1 page

Top 10 Tags

All Tags (2094)